Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16266000 | 0.91 | MGMT (0.52) | MGMTADORA2AADORA1PDPK1GDA | |
| SCHEMBL5998120 | 0.84 | PIK3CA (0.46) | MGMTADORA2AADORA1PDPK1GDA | |
| SCHEMBL10380576 | 0.82 | PIK3CA (0.45) | MGMTADORA2AADORA1PDPK1GDA | |
| SCHEMBL1029868 | 0.77 | SMN1; SMN2 (0.51) | PDPK1CDK2PIK3CAMTORPIK3CG | |
| SCHEMBL4052354 | 0.77 | DHFR (0.52) | MGMTADORA2AADORA1DHFRCYP1A2 | |
| SCHEMBL540121 | 0.77 | ADORA2A (0.49) | MGMTADORA2AADORA1DHFRCYP1A2 | |
| SCHEMBL2933190 | 0.75 | ADORA1 (0.69) | MGMTADORA2AADORA1PDPK1GDA | |
| SCHEMBL887880 | 0.75 | PDPK1 (0.51) | MGMTADORA2AADORA1PDPK1GDA | |
| SCHEMBL27691725 | 0.72 | ADORA2A (1.00) | MGMTADORA2AADORA1PDPK1GDA | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.71 | PDPK1 (1.00) | MGMTADORA2AADORA1PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105897-A1 | METHOD FOR DETECTING GENOMIC MUTATION THROUGH NUCLEIC ACID PATTERN-BASED PURIFICATION, AND DISEASE DIAGNOSIS METHOD USING SAME | 광주과학기술원 | 2025-05-22 | — | — | WO | claimed |
| US-20250154557-A1 | COMPOSITION FOR SELECTING NUCLEIC ACIDS OF INTEREST, AND A METHOD FOR SELECTING NUCLEIC ACIDS USING THEREOF | GWANGJU INST SCIENCE & TECH (KR) | 2025-05-15 | — | — | US | claimed |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20210292757-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-09-23 | — | — | US | claimed |
| EP-3865576-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| US-10870849-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | claimed |
| US-10837013-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | claimed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | claimed |
| EP-3401407-A1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | Kabushiki Kaisha Dnaform (JP) | 2018-11-14 | — | — | EP | claimed |
| US-20130041010-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | claimed |
| US-8067162-B2 | Replication; hybridization; kits | RIKEN (JP) | 2011-11-29 | — | — | US | claimed |
| EP-2341943-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | Dicerna Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| US-20100331389-A1 | Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides | DICERNA PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | claimed |
| EP-1114827-B1 | NOVEL NUCLEIC ACID BASE PAIR | JAPAN SCIENCE & TECH AGENCY (JP) | 2010-11-17 | — | — | EP | claimed |
| EP-2223931-A1 | Novel nucleic acid base pair | Japan Science and Technology Agency (JP) | 2010-09-01 | — | — | EP | claimed |
| WO-2010033225-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | claimed |
| US-20090286247-A1 | Novel nucleic acid base pair | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-11-19 | — | — | US | claimed |
| US-20050191689-A1 | Novel nucleic acid base pair | HIRAO, ICHIRO (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1114827-A1 | NOVEL NUCLEIC ACID BASE PAIR | Japan Science and Technology Corporation (JP) | 2001-07-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | MGMT 3561/4885ADORA2A 224/4885ADORA1 434/4885 |
| US-20090286247-A1 | Novel nucleic acid base pair | SNRPE, NSUN2, NSUN3 | MGMT 3493/4885ADORA2A 3160/4885ADORA1 3886/4885 |
| US-20050191689-A1 | Novel nucleic acid base pair | SNRPE, NSUN2, NSUN3 | MGMT 3493/4885ADORA2A 3160/4885ADORA1 3886/4885 |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | MGMT 3538/4885ADORA2A 4297/4885ADORA1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.